GB2597299A - Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain - Google Patents

Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain Download PDF

Info

Publication number
GB2597299A
GB2597299A GB2011143.1A GB202011143A GB2597299A GB 2597299 A GB2597299 A GB 2597299A GB 202011143 A GB202011143 A GB 202011143A GB 2597299 A GB2597299 A GB 2597299A
Authority
GB
United Kingdom
Prior art keywords
cbd
preparation
thc
seizures
cannabidiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB2011143.1A
Other languages
English (en)
Other versions
GB202011143D0 (en
Inventor
Adam Checketts Daniel
James Craig Kevin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Research Ltd
Original Assignee
GW Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Research Ltd filed Critical GW Research Ltd
Priority to GB2011143.1A priority Critical patent/GB2597299A/en
Publication of GB202011143D0 publication Critical patent/GB202011143D0/en
Priority to PCT/EP2021/069894 priority patent/WO2022017955A1/fr
Publication of GB2597299A publication Critical patent/GB2597299A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB2011143.1A 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain Pending GB2597299A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB2011143.1A GB2597299A (en) 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
PCT/EP2021/069894 WO2022017955A1 (fr) 2020-07-20 2021-07-15 Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies structurales du cerveau

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2011143.1A GB2597299A (en) 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain

Publications (2)

Publication Number Publication Date
GB202011143D0 GB202011143D0 (en) 2020-09-02
GB2597299A true GB2597299A (en) 2022-01-26

Family

ID=72339074

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2011143.1A Pending GB2597299A (en) 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain

Country Status (2)

Country Link
GB (1) GB2597299A (fr)
WO (1) WO2022017955A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015193668A1 (fr) * 2014-06-17 2015-12-23 Gw Pharma Limited Utilisation de cannabidiol dans le traitement de l'épilepsie
WO2016203239A1 (fr) * 2015-06-17 2016-12-22 GW Research Limited Utilisation de cannabinoïdes dans le traitement de l'épilepsie
WO2019145700A1 (fr) * 2018-01-24 2019-08-01 GW Research Limited Utilisation de cannabinoïdes dans le traitement de l'épilepsie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) * 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015193668A1 (fr) * 2014-06-17 2015-12-23 Gw Pharma Limited Utilisation de cannabidiol dans le traitement de l'épilepsie
WO2016203239A1 (fr) * 2015-06-17 2016-12-22 GW Research Limited Utilisation de cannabinoïdes dans le traitement de l'épilepsie
WO2019145700A1 (fr) * 2018-01-24 2019-08-01 GW Research Limited Utilisation de cannabinoïdes dans le traitement de l'épilepsie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Margaret Gedde, 9-11 September 2014, "Clinical Experience with Cannabis in Treatment-Resistant Pediatric Epilepsy", Available via: http://www.theroc.us/images/gedde_presentation.pdf *

Also Published As

Publication number Publication date
GB202011143D0 (en) 2020-09-02
WO2022017955A1 (fr) 2022-01-27

Similar Documents

Publication Publication Date Title
US20230285425A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
US20230285422A1 (en) Use of cannabidiol in the treatment of seizures associated with mutations in the syngapi gene
GB2597299A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597285A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597297A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597316A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597296A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury
GB2597284A (en) Use of cannabidiol in the treatment of seizures associated with multifocal epilepsy
GB2597318A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597311A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597317A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597319A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597300A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597278A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597305A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597323A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597290A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597287A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2599340A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597280A (en) Use of cannabidiol in the treatment of seizures associated with auriculotemporal syndrome
GB2597288A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597293A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597314A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597308A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597307A (en) Use of cannabidiol in the treatment of seizures associated with encephalitis